Butterfly Network Stock Is The VCOM Alliance Changing The Growth Case
- Butterfly Network and the Edward Via College of Osteopathic Medicine recently agreed a long-term ultrasound education alliance that includes one-probe-per-student deployment, discounted devices for current cohorts and ongoing data sharing through Butterfly’s cloud platform.
- The multi-year Bridge Neurotech R&D agreement signals that Butterfly Network’s Ultrasound-on-Chip technology is being licensed into emerging non-surgical brain interface applications, adding a distinct use case beyond traditional point-of-care imaging.
- We will now see how Butterfly Network’s alliance that gives every incoming VCOM student a Butterfly iQ3 could reshape the investment narrative.
Butterfly Network Investment Narrative Recap
To own Butterfly Network, you need to believe handheld ultrasound can move from niche tool to everyday instrument across hospitals, clinics, training programs and eventually more decentralized care. The VCOM alliance leans in that direction by seeding thousands of new clinicians on Butterfly hardware and software, which directly targets concerns about slow enterprise and medical school deal cycles.
The near term swing factor still sits in execution on large deployments and software adoption, while the biggest risk is ongoing losses combined with a high P/S multiple and no near term path to profitability. If these new alliances fail to translate into recurring software usage and follow on contracts, the impact on the story is limited.
The VCOM partnership looks most relevant because it addresses two core catalysts in one move. It ties Butterfly Network’s hardware to education and workflow via cloud software, and it builds a longitudinal dataset that can feed Compass AI and other clinical apps, which is where higher margin recurring revenue sits.
For you, the practical question is whether this kind of multi year education and Lighthouse program meaningfully reduces the risk of flat domestic revenue and weak subscription renewals. If device placements convert into long lived software relationships as these students move into practice, it supports the thesis that enterprise and medical school deals can offset volatility in global health projects and help absorb the cost of heavy R&D.
Butterfly Network's current analyst story points to US$258.1 million in revenue and US$32.5 million in earnings by 2029. That path assumes revenue grows at 32.0% a year and earnings shift from a loss of US$74.8 million today to the projected profit, a swing of roughly US$107 million.
Uncover why Butterfly Network's fair value indicates a 57% potential upside to its current price that could narrow quickly.
Exploring Other Perspectives
One alternate view focuses on execution risk rather than the VCOM-style education flywheel. The most cautious Butterfly Network analysts were already modeling revenue of about US$217.2 million and earnings of roughly US$27.3 million by 2029, paired with a very high implied P/E. That more pessimistic setup could shift if you think this alliance changes the adoption curve.
Explore 4 other Butterfly Network fair value estimates, including one that suggests as much as 75% downside from the current price!
The Verdict Is Yours
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Butterfly Network research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
- See our latest analysis for Butterfly Network. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Butterfly Network's overall financial health at a glance.
Looking For More Investment Ideas Beyond Butterfly Network?
Once you have formed a view on Butterfly Network, it can help to set it against a wider watchlist of companies with different strengths, risk profiles and income potential. The Simply Wall St Screener lets you do exactly that by filtering the market down to a focused, research ready set of stocks.
- If you want potential mispricing on quality to be your starting point, scan our hand picked 33 high quality undervalued stocks that combine solid fundamentals with attractive valuations.
- If capital preservation matters most to you, build a shortlist from the 32 resilient stocks with low risk scores that score well on financial resilience and lower volatility factors.
- If you are hunting for future leaders before they hit the mainstream, start with the 20 high quality undiscovered gems and see which smaller companies already show strong underlying metrics.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com